Patient
SITE004-0128
completed Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE004 (DEU) (Dr. Tanaka)
consented 2026-02-05
Adverse events
6
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 6
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-01-07 (study day 152); relationship: not assessed
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-10-19 (study day 72); relationship: not assessed
Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-10-18 (study day 71); relationship: RELATED
Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-01 (study day 54); relationship: not assessed; serious criteria: life-threatening
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-09-08 (study day 31); relationship: not assessed
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-08-25 (study day 17); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.